The International Association for the Study of Lung Cancer (IASLC) complies with the Standards for Commercial SupportSM of the Accreditation Council for Continuing Medical Education (ACCME). IASLC applies these Standards throughout the educational program process—from development through implementation—to ensure independence of continuing medical education activities.
In compliance with ACCME Standards, individuals in a position to control the content of a CME activity must disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant” financial relationships as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. Individuals who refuse to disclose relevant financial relationships are not allowed to have control of, or responsibility for, the development, management, presentation or evaluation of CME activities. All disclosures are reviewed for potential conflicts and appropriate steps for resolution are taken when needed. Additionally, individuals must agree to comply with specific rules (attestations) to ensure content is balanced and evidence-based, does not promote the business interests of a commercial entity, and conforms to the generally accepted standard of experimental design, data collection and analysis. Presenters are also required to clearly identify any non-FDA approved uses of products. IASLC monitors presentations for quality and compliance through direct observation by staff and/or IASLC CME committee members, and through attendee feedback received from evaluation surveys.
For the IASLC 2020 North America Conference on Lung Cancer (NACLC 2020), presenter disclosure information will be available for viewing as of August 28, 2020. Presenters are also required to include a disclosure slide listing all relevant financial relationships with commercial interests. CME related questions should be directed to IASLC at cme at iaslc.org.
Accreditation and Credit Designation Statements
The International Association for the Study of Lung Cancer is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The International Association for the Study of Lung Cancer designates this Other activity (blended live, simulive and on-demand materials) for a maximum of 13.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The IASLC 2020 North America Conference on Lung Cancer is designed to meet the educational needs of researchers and healthcare professionals who diagnose and treat patients with lung cancer and other thoracic malignancies, including medical oncologists, thoracic surgeons, pulmonologists, radiation oncologists, radiologists, pathologists, advanced practice nurses, physician assistants and nurses. The conference is also designed to provide a forum for lung cancer patients and patient advocates to receive education and share their perspectives with the lung cancer community.
At the conclusion of this activity, participants will be able to:
Apply evidence-based recommendations and clinical practice guidelines to diagnose and treat patients with lung cancer and other thoracic malignancies.
Describe the impact of COVID-19 on lung cancer care, research, and prevention efforts.
Describe scientific advances in lung cancer and other thoracic malignancies.
Synthesize research from clinical trials and translational studies to deepen knowledge within primary specialty area(s) and broaden knowledge of other specialties.
Advocate for lung cancer prevention strategies including tobacco control, smoking cessation, reducing environmental risks, and implementing early screening.
Engage and empower patients to become active participants in their treatment.
The official language of the IASLC 2020 North America Conference on Lung Cancer is English.
The information presented at the IASLC 2020 North America Conference on Lung Cancer is that of the contributing faculty and does not necessarily represent the views of the International Association for the Study of Lung Cancer and/or any named commercial entity providing financial support. Specific therapies discussed may not be approved and/or specified for use as indicated by the faculty presenters. Therefore, before prescribing any medication, please review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse effects.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Keep up to date with Conference News & Alerts. Sign Up